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Child mortality after high-titre measles vaccines: 
prospective study in Senegal 
MICHEL GARENNE ODILE LEROY JEAN-PIERRE BEAU 
IBRAHIMA SENE 
The use of Edmonston-Zagreb high-titre (EZ-HT) 
vaccine at age 6 months has been recommended for 
countries in which measles before the age of 9 
months is a substantial cause of death, but little is 
known about the long-term effects of high-titre live 
measles vaccines given early in life. In a randomised 
vaccine trial in a rural area of Senegal, children were 
randomly assigned at birth to three vaccine groups: 
EZ-HT at 5 months (n=336); Schwatz high-titre 
(SW-HT) at 5 months (n=321); and placebo at 5 
months followed by standard low-titre Schwarz 
vaccine at 10 months (standard: n=358). All 
children were prospectively followed for 24-39 
months in a well-established demographic 
surveillance system. Child mortality after 
immunisation was significantly higher in the two 
groups which received high-titrevaccines than in the 
group given the standard vaccine. The relative risk of 
death was 1.80 (95% confidence interval [CI] 
1.1 8-2-74; p=0.007) in the E - H T  group and 1 -51 
(0.97-2-34; p=0-07) in the SW-HT group 
compared with the standard group. The three 
vaccine groups were comparable as regards various 
social, family, and health characteristics, and there 
was no difference in mortality between children who 
received the standard vaccine and those who were 
eligible for the trial but did not take part for various 
reasons. The higher risk of death in the two high-titre 
vaccine groups remained significant in multivariate 
analyses. These findings suggest a need to 
reconsider the use of high-titre measles vaccines 
early in life in less developed countries. 
Lancet 1991; 338: 903-07. 
Introduction 
Measles is a leading cause of child mortality and 
morbidity in less developed countries.'Z It is rare in infants 
under 4 months old owing to the protection afforded by 
transplacentally acquired matemal antibodies. In less 
developed countries the majority of infants bemme 
susceptible shortly after the age of 4 months. Measles 
case-fatality rates are highest at younger ages, especially 
between 4 and 12 mon th^.^ 
In developed countries low-titre, live, attenuated measles 
vaccines are safe, immunogenic, and effective when given in 
the second year of lie. In less developed countries, the 
profile of matemal antibodies M e r s  somewhat$" and the 
usually recommended age for vaccination is 9 months? 
However, th is  strategy leaves open a window of high risk of 
death from measles between the ages of 4 and 9 months. 
The live Fdmonston-Zagreb (EZ) vaccine7 produces a 
better immunological response than standard vaccines even 
when given as early as 4 months of age.a1o Two possible 
explanations for the better performance of this vaccine are 
the strain and the titre, often 10-100 times higher than that 
P M  rg 
of standard vaccines. Several vaccine trials have compared 
the immunological responses and adverse reactions after 
Wonston-Zagreb vaccines of low, medium, and high 
titres with those of other measles vaccines of the same titres 
in children younger than 9 
The use of Edmonston-Zagreb high-titre vaccine has 
been recommended "at age 6 months in countries in which 
measles before the age of 9 months is a significant cause of 
death"." However, little is known about the long-term 
effects of high-titre live measles vaccines given early in life. 
Subjects and methods 
The study area was located near Niakhar, in the department of 
Fatick in central Senegal. It included 30 villages, inhabited by about 
25 O00 people of Sereer origin. A comprehensive demographic 
surveillance system based on yearly censuses and weekly visits to 
households to register vital events was in progress before the study 
started and has been maintained since. 
A randomised vaccine mal of the efficacy, safety, and 
immunogenicity of two high-titre live measles vaccines, 
Edmonston-Zagreb (EZ-HT) and Schwarz (SW-HT), was carried 
out in 1987-89.18 Although the primary objective of the study was 
clinical efficacy, a mortality surveillance was set up both to check 
safety and to evaluate the vaccination strategy. In addition to the 
routine surveillance system, independent checks on child deaths 
were made in October, 1990, and February, 1991. More details on 
the study area and on the data collection system can be found 
elsewhere.1gs1 
The study was approved by the Ministère de la Santé Publique, 
Dakar, Senegal; by ORSTOM authorities (Institut Français de 
Recherche pour le Développement en Coopkation, Paris); and by 
the ethical committee of the British Medical Research Council, 
Fajarah, The Gambia. Oral hfomed consent was obtained from 
the parents of the participants; 20% of parents refused to allow their 
childrentoparticipate. Duringthe3yea.r~oftheproject~vaccination 
was available to everyone, and free drugs and medical services were 
provided to all children and adults of the study population. As a 
consequence, overall mortality was substantially lower than during 
the 3 preceding years (1984-86). 
Three measles vaccines were supplied by the manufacturers: 
EZ-HT (batch 81/3; titre 5.4 log,, plaque-forming units [pfu]; 
Institute of Immunology, Zagreb, Yugoslavia); SW-HT (batch 
0980; titre 5.4 log,; pfu; Institut Mérieux, Lyon, France), and a 
Schwarz standard vaccine (titre 3.7 log,, pfu, Institut Mérieux). 
A placebo produced by Institut Mérieux as a standard 
vaccine preparation without the active particles was also used. The 
titre of the vaccines monitored throughout the project remained 
stable. 
The study was carried out within the framework of the National 
Expanded Programme for Immunisation of Senegal. Children were 
vaccinated at ages 3,5, and IOmonths. At each session they received 
an injection of diphtheria, pertussis, tetanus vaccine and inactivated 
poliomyelitis vaccine; in addition they received BCG at 3 months 
and yellow fever vaccine at 10 months. High-titre measles vaccines 
were given only at 5 months (mean 22 [SD 23 weeks), and the 
standard measles vaccine was given at 10 months (after placebo at 5 
months). By age 10 months all children who came to the three 
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No assigned at bitth 
No e n d e d  at 5 mo 
Person-months of 
Mean (SD) duration of 
follow-up 
TABLE I-ENROLMENT, DURATION OF FOLLOW-UP, LOSS TO 
FOLLOW-UP, AND MORTALITY IN STUDY POPULATION 
Trial participants 
Non- 
EZ-HT SW-HT Standard participants 
526 527 539 (- 189)* 
336 321 358 388 
9522 9208 10416 10551 
29.1 (9.2) 
32 
23 
follow-up (mo) 28.3 (9.7) 28.6 (9.9) 
No of non-accidental 
deaths during 
follow-up 
No lost to follow-up 
*Deaths and outmigrants before 5 mo. 
27.2 (9.8) 
35 
43 
Months of 
follow-up after 
vaccination 
(age) 
TABLE Il-SURVIVAL AFTER 5 mo BY VACCINE GROUP 
Survival (SE) per 1000 survivors at 5 mo 
Trial participants 
Non- 
EZ-HT 1 SW-HT I Standard participants 
Age of mother (yr) ' 
% of literate mothers 
No of residents in compound 
Distance to dispensaty (km) 
Mortality of older siblings of same mother (per 1000 
969 9 (9.4) 94643 (12.6) 963.5 (9.9) 976.2 (7.9) 
932.8 (13.8) 927.8 (14.5) 943.4 (12.3) 943.6 (12.0) 
904.7 (16.3)t %.O (16.7)t 937.6 (12.9) 935.2 (12.8) 
24 (29) 876.3 (18.3)* 889 O (17.7) 922.8 (14.3) 912.2 (14.8) 
50 (35) 859.8 (194)* 870.4(19.2)t 910.6 (15.3) 901.2 (16.0) 
36 (41) 831.8 (22.5)* 858.6 (20.7)t 906.3 (15.9) 901.2 (16 O) 
Significance of difference from standard group. *pcO 05. t < O  10 (both two- 
tailed) 
sessions were completely vaccinated. Children who missed a session 
could come later to complete their vaccination series. 
At birth, children were randomly assigned by means of a 
computer random generator to one of three vaccine groups: EZ-HT 
vaccine at 5 months; SW-HT vaccine at 5 months; or placebo at 5 
months and standard measles vaccine at 10 months (standard 
schedule). Some children bom during the study period did not take 
part in the study because the parents refused, the 5 months 
vaccination was missed, or vaccination was contraindicated. These 
non-participants were eligible for regular vaccinations, including 
measles at 9-10 months, and were included in the surveillance for 
survival in the same way as the participants. 
Criteria for inclusion in the study were: birth to a resident mother 
betweem Feb 1, 1987, and May 31, 1988; clinic attendance at 5 
months for vaccination and parental agreement to participation; 
absence of any contraindication to measles vaccination (evolving 
infectious disease, history of convulsion, previous measles infection, 
or previous measles vaccination); and no revaccination with another 
measles vaccine between 5 and 10 months of age. 
Investigators and field workers were unaware which type of 
measles vaccine had been given until the code was broken in June, 
27.7 (6.5) 
23 (14) 
3.8 (2.3) 
3.7 (1.2) 
EZ.HT 
5 1 1  17 23 29 35 41 
Age (mo) 
Fig I-Cumulativa mortality from 5 t o  41 months, according to 
1989. Furthermore, the code was not revealed to the field workers 
who routinely recorded deaths or to the two physicians who 
reviewed the verbal autopsy questionnaires until the review was 
completed. Physicians and nurses who were treating patients in the 
local dispensaries knew nothing about vaccine assignment, because 
there was no mention of the type of measles vaccine on the health 
cards or on the dispensary register. 
Survival of children was analysed in a monthly lifetable 
(Kaplan-Meier product l i t  estimates). Multivariateanalyses were 
carried out with linear logistic regressions on age-specific death 
rates. Proportional hazard models were also hied, but they did not 
fit the situation well, because of the very smng seasonal pattern of 
mortality among children. Standard testing procedures were 
applied, and two-tailed tests were used. 
vaccine group. 
Results 
1015 children were included in the vaccine trial: 336 in the 
EZ-HT group, 321 in the SW-HT p u p ,  and 358 in the 
standard group; 388 children assigned at birth did not take 
part in the study (table I). By October, 1990, there was an 
excess of non-accidental deaths in both groups vaccinated 
with the high-titre vaccines (table I). There was only 1 
accidental death-among the non-participants. 
In a life-table analysis, children who received the EZ-HT 
vaccine at 5 months had significantly higher mortality at 41 
months than children in the standard group (table II, fig 1): 
the relative risk of death was 1-80 (95% confidence interval 
[CI] 1.18-2.74; p=0@07). Children who received the 
SW-HT vaccine at 5 months also had a higher mortality 
than children in the standard group (relative risk 1.51 [95% 
CI 0.97-2341; p = 0.07). There was no significant difference 
TABLE III-COMPARISON OF VACCINE GROUPS ACCORDING TO CHARACTERISTICS OF FAMILY AND INFANT AT 5 mo 
Mean (SD) 
- 
livebirths) 
% outmigrant children 
Death rate in compound of residence (per 1000) 
Infant at 5 mo 
Age at vaccination (wk) 
Height (an) 
Left upper mid-arm circumference (mm) 
Weight (kg) 
313 (25) 
6.5 (1.3) 
17.6 (20) 
21.6 (2.1) 
6.45 (1.00) 
63.0 (26.0) 
132 (13) 
Trial participants 
SW-HT 
28.1 (7.8) 
3.8 (1-2) 
23 (18) 
3.9 (2.5) 
309 (26) 
4.7(1-2) 
17.9 (25) 
216 (2.0) 
6.46 (1.00) 
63.3 (26.0) 
132 (13) 
3.2 (1.0) 
23 (IS) 
3.9 (2.6) 
313 (25) 
8-9 (1.3) 
17.3 (23) 
213 (1.9)* 
640 (0.90) 
63.2 (24.0) 
132 (13) 
Non-participants 
28.6 (7.0) 
3.6 (1.1) 
23(19) 
4.1 (2.3) 
297 (23) 
11.1 (1.6) 
20.0 (25) 
*With placebo vaccine: standard Schwarz vaccine given at 10 mo. 
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Fig 2-Trends in mortality at age 5-40 months, cohorts 
in cumulative mortality at 41 months between the EZ-HT 
and SW-HT groups (168 vs 141 per loo0 between 5 and 41 
months) or between the standard group and the non- 
participant group (93 vs 99 per lO00). 
Analyses to determine whether the va&e groups were 
comparable showed that they were similar for the variables 
listed in table III and mortality in the randomised groups 
from bkth to 4 months. Children in the non-participant 
group were also from families with a similar background. 
Children in the three vaccine groups were similar at 5 
months in average age at vaccination, weight, height, and 
arm circumference (table III). 
T o  exclude the possibility that mortality in the standard 
vaccine group was abnormally low, the mortality rates in the 
vaccine groups were compared with the rate predicted from 
trends in mortality since 1982 (fig 2). Extension of the trends 
predicts a mortality of 91 per lo00 during the study period 
compared with the 93 per lo00 found in the standard group. 
There was no significant-difference within the study 
group in mortality by,sex: the relative risk of death 
( fde /male)  was 1-20 in the EZ-HT group (p = 0.497), 
1-14 in the SW-HT group (p = 0.636), O64 in the standard 
group (p=0*195), and 1.16 among the non-participants 
(p = 0.640). Baseline data, going back to 1963, in the same 
population showed no difference in mortality by sex beyond 
the neonatal period. 
The effect of various correlates of mortality was 
investigated in linear logistic regressions, which allowed a 
better fit of the mortality pattem with strong seasonal 
variation and changes with age. Periods of exposure to 
mortality were divided into 4month periods corresponding 
to 'the three seasons of the year: July to October (rainy), 
November to February (dry, cool), and March to June (dry, 
1982-88. 
TABLE IV-RESULTS OF MULTIVARIATE LOGlT ANALYSIS OF 
Covariate 
Model I :  all combined 
Vaccine: EZ-HT 
Vaccine: SW-HT 
Model2: by vaccine 
Age (EZ-HT) 
Age (SW-HT) 
Age (standard) 
Standard = reference. 
*p<o.o5 tP<O.lO.  
DEATH RATES 
5.16 
Age [mo)  17-28 
c 
70- 
6 0 -  
50- 
s 40-  
n 
3 30- 
m 
2 
r 
.-  - 8 20- 
= 10- 
n- " 
U-HT SW.HT Standard 
Fig 3-Age-specific death rates, according t o  vaccine group. 
hot). Separate models were tested for each vaccine group. 
Results of the effects of the vaccines (relative risks) remained 
stable with control for all other variables that were available: 
age, sex, age at vaccination, season, season of vaccination, 
measles antibody titre at 5 months, and seroconversion 
between 5 and 10 months of age. Odds ratios associated with 
high-titre vaccines remained stable in the various 
multivariate analyses. In the final model, the odds ratios 
were 1.71 (p=O*O19) for EZ-HT and 1-49 (p=O.O93) for 
SW-HT (table IV). The coefficient of the A y  season was 
always high and significant.yd was greater in the two 
HT-vaccinated groups &,an in'the standard group. Sex, titre 
of antibodies at 5 monthsiand seroconversion between 5 and 
10 months of age were not significant variables in any group. 
The same multivariate analyses by vaccine group showed 
that the coefficient of age in the EZ-HT group was close to 
zero: this finding shows that mortality remained consistently 
high in the second and third year after the EZ-HT vaccine, 
whereas in other groups death rates declined substantially 
with age as would be expected (fig 3). The lack of decline in 
mortality rates with age of children is a cause for concem. 
The finding of excess mortality in the vaccinated groups 
was possible for two reasons: the incidence of measles was 
low during the study period (69 cases among the study 
children), otherwise there might have been measles deaths 
between 5 and 10 months in the standard group (who 
received the placebo at 5 months); and the measles 
case-fatality rate was also low as a result of intensive medical 
care provided during the project. The only child who died 
from measles was away from the study area and was a 
non-participant in the study. 
Only verbal autopsies were available to evaluate causes of 
death. Few children died in hospital. Most of the deaths 
were apparently from common diseases of childhood (table 
v). In the EZ-HT vaccine group 9 deaths were attributed to 
kwashiorkor and 5 to viral diseases other than measles. 5 of 6 
dysentery deaths and 8 of 10 deaths due to acute respiratory 
infections were in the SW-HT group. The only accidental 
TABLEV-DISTRIBUTION OF DEATHS BY REPORTED CAUSE 
Probable cause 
Diarrhoea, dysentery 
Malaria 
Malnutrition 
Acucerespiratoly . 
Measles 
Other infecrious diseases 
Accident 
unknown 
Total 
Trial participants 
O O 
jtandàri 
17 
7 
5 
O 
O 
1 
O 
2 
32 - 
Non- 
3articipants 
21 
2 
4 
2 
1 
3 
I 
, 2  
36 
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death and the only death attributed to measles were among 
the non-participants. The frequency of other diseases and 
unknown causes of death was similar in the four groups. 
Discussion 
The demographic surveillance system developed in 
Niakhar is an unusually reliable system of data collection 
that is unique in tropical Africa. Weekly visits to households 
ensure accuracy of dates of births and deaths, and yearly 
updating of maternity histories and full-scale census takiig 
by roll call from computer printouts guarantees the 
complete recording of vital events. 
Differences in mortality among the groups were tested by 
eight statistical procedures (life-table, death rate, probability 
of death, age-standardised death rates, linear logistic 
regression, proportional hazards, log-rank tests, and 
simulations). They showed a consistent level of significance 
of mortality differences from the standard vaccine group 
(p = 0.007 to 0.024 for the EZ-HT group and p = 0.041 to 
0.102 for the SW-HT group). 
The consistency of the data, both in the groups vaccinated 
with high-titre vaccines and in the groups not given the 
high-titre vaccines, was striking. The probability of 
concurrent occurrence of at least 50 deaths in the EZ-HT 
group and at least 42 deaths in the SW-HT group was very 
Sinœ the goal of the study was to compare two 
strategi-vaccination at 5 months with high-titre vaccines 
versus vaccination at 10 months with a standard vaccine- 
survival after 10 months was also investigated. The two 
groups receiving the high-titre vaccines at 5 months had a 
similar excess mortality between 10 and 41 months over that 
in the standard vaccine group. Relative risks of deaths were 
2.50 (95% CI 1524.13; p = O.OOO4) in the EZ-HT group 
and 1-73 (1.00-2.98; p=O56) in the SW-HT group. 
The fact that children who migrated out of the study area 
were removed (censored) at the time of their move did not 
affect the results. An attempt to find those who died after 
outmigration showed that their inclusion would not have 
affected the results. There were 11 death-3 in the EZ-HT 
group, 1 in the standard group, and 7 in the non-participant 
group, which included most of the outmigrants. The 
difference between the EZ-HT and the standard group 
would have been even larger (20 deaths) if deaths among 
migrants had been included. 
Later cohorts also were vaccinated with the EZ-HT 
vaccine at 5 months: those bom between June, 1988, and 
January, 1989, were randomised and those bom between 
March, 1989, and May, 1990, werenot randomised. It is too 
early to judge the mortality of those cohorts, but mortality in 
the EZ-HT group, although lower than in previous cohort, 
has not declined with age. 
The prevalence of HIV infection was low in the study 
area: only 2 of 401 project children sampled at age 3 months 
had HIV antibodies, and neither died. A seroprevalence of 
05% was found among pregnant mothers of the study area. 
Thus, HIV infections could not have had a role in this study. 
Since the high-titre vaccines produced by two different 
companies had similar effects, it is unlikely that the excess 
mortality was due to a production defect such as 
contamination. Furthermore, both vaccines had high 
immunogenicity, high efficiency, and only mild side-effects.18 
It is beyond the scope of this paper to document biological 
low (p < O~oopl). 
plausibility. However, previous studies suggest that 
interaction of live measles vaccines with child immunity is 
possible. Short-term effects of live virus vaccines on child 
immunity have been In a study in the Niakhar 
area, a low response to yellow fever vaccination was found 
when it was given in association with the EZ-HT vaccine 
. (personal communication, Dr  J-P. Gonzalks). The wild 
measles virus has severe adverse short-term effects on 
immunity and nutritional status of children, in particular on 
nitrogen metabolism2' and vitamin In addition, the wild 
measles virus can have long-term effects, such as subacute 
sclerosing panen~ephalitis.2~ 
There was no reason to suspect excess mortality after 
measles vaccines in the study area: earlier findings there and 
in a nearby area30 showed that survival was better among 
children vaccinated with a standard measles vaccine, even 
when it was given before 6 months of age. This fiding 
suggests that the high titre may be the main cause of the 
effect. 
Excess mortality became significant for the first time in 
the spring of 1990, several months after the last child 
completed the vaccination series. This effect is partly due to 
the sample size, because the number of deaths was too small 
before that time for a significant relative risk to show, and 
partly because most excess deaths were concentrated in the 
high mortality age group, which lies from 18 to 41 months in 
this population. 
A quick cost-benefit analysis suggests that the strategy of 
using high-titre vaccines early in life is not worth while: 
between 48 (SW-HT) and 75 deaths (EZ-HT) per lo00 
children reaching age 5 months seemed to be associated with 
the use of high-titre vaccines. This number exceeds by far 
the reduction in mortality expected from the early 
vaccination, estimated to be 4per 1,000 children reaching age 
5 months (incidence of 42/1o00 between 5 and 10 months 
multiplied by case-fatality rate of 10%). 
If these findings are confirmed in other settings, other 
strategies to reduce mortality from early measles should be 
developed. The low titre AIK-C vaccine seemed to produce 
a good immunogenic response at 6 months among Togolese 
~hi1dren.l~ In Niakhar, the standard measles vaccines were 
safe, even when given at 4-6 months, and may well prevent 
deaths from measles. Since most complications of measles 
occur during the second and third weeks after onset, early 
treatment is possible. A systematic treatment of 
complications in the Niakhar study reduced the case-fatality 
rate among children below 3 years of age by 78%. 
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Intestinal permeability, mucosal injury, and growth 
faltering in Gambian infants 
P. G. L u "  C.  A. NORTHROP-CLEWES R. M. D o m s  
There is controversy over whether children in 
developing countries can catch up on their growth 
rates after bouts of diarrhoea. A factor influencing 
catch-up growth is the extent and duration of 
mucosal injury. To explore the relation between 
intestinal disease and growth performance, a non- 
invasive test of intestinal integrity, the 
1actulose:mannitol permeability test, was done 
regularly on children aged 2-1 5 months, whose 
growth was monitored over a mean of 7.5 months. 
The study revealed persistent abnormalities in the 
small bowel mucosa of 2-15 month old Gambian 
infants and a negative correlation between these 
abnormalities and growth. Up to 43% of observed 
growth faltering can be explained on the basis of 
these long-term intestinal lesions. 
Lancet 1991 : 338: 907-1 O. 
Introduction 
Whether diarrhoeal disease is responsible for the 
progressive deterioration of nutritional status so regularly 
observed in infants in developing countries remains a 
strongly debated issue."4 That episodes of diarrhoea cause 
short-term faltering in both height and weight development 
is accepted. What is disputed is whether children are able to 
catch up with their expected growth trajectory after such 
episodes. 
It is important to the argument that diarrhoea be regarded 
as a symptom, not a disease. Just as the pathophysiology of 
diarrhoea varies with precipitating agents, so will the impact 
of the illness on weight and height growth and the extent of 
mucosal injury. Episodes associated with a systemic 
inflammatory reaction can be expected to result in severe 
growth faltering during the acute phase of the illness, but in 
the absence of intestinai injury, catch-up growth could be 
rapid. In contrast, if the diarrhoea is accompanied by 
damage to the mucosa of the small intestine then full 
catch-up growth cannot be expected until such injury has 
been repaired. 
Little is known about the time taken for restoration of 
normal mucosal structure and function following injury 
mainly because of difficulties in measuring intestinal status. 
Until recently mucosal damage could be assessed only by 
endoscopy and/or biopsy of the small intestine, but the 
introduction of non-invasive techniques for estimating 
specific aspects of mucosal function and integrity has 
enabled repeated measurements to be made even under field 
 condition^.^^ Here we describe the use of one such method, 
the dual-sugar intestinal permeability test: to assess small 
intestinal mucosal status of rural Gambian infants aged 2-15 
months at risk of malnutrition. In this test, a low % 
1actulose:mannitol ratio suggests mucosal normality 
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